Long-Term Symptoms Among Adults Tested for SARS-CoV-2 — United States, January 2020–April 2021 | Overlooked Shortcomings of Observational Studies of Interventions in Coronavirus Disease 2019: An Illustrated Review for the Clinician | Long-Term Symptoms Among Adults Tested for SARS-CoV-2
Ivermectin Intended for Animals: Letter to Stakeholders – Do Not Use in Humans as a Treatment for COVID-19 | Characteristics and Outcomes of Women With COVID-19 Giving Birth at US Academic Centers During the COVID-19 Pandemic | Children and COVID-19: State-Level Data Report | Long COVID – the physical and mental health of children and non-hospitalised young people 3 months after SARS-CoV-2 infection; a national matched cohort study (The CLoCk) Study. | Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021 | 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study | Convalescent plasma recommendations from IDSA
Unvaccinated COVID-19 hospitalizations cost the U.S. health system billions of dollars | Comirnaty and PfizeSARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years | A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadth | Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting |.Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers | COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With COVID-19 | COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection
The SARS-CoV-2 Delta variant and its sublineages (B.1.617.2, AY.1, AY.2, AY.3; ) can cause high viral loads, are highly transmissible, and contain mutations that confer partial immune escape [2,3]. Using PCR threshold cycle (Ct) data from a single large contract laboratory, authors show that individuals in Wisconsin, USA had similar viral RNA loads in nasal swabs, irrespective of vaccine status, during a time of high and increasing prevalence of the Delta variant. Infectious SARS-CoV-2 was isolated from 51 of 55 specimens (93%) with Ct <25 from both vaccinated and unvaccinated persons, indicating that most individuals with Ct values in this range (Wilson 95% CI 83%-97%) shed infectious virus regardless of vaccine status. Notably, 68% of individuals infected despite vaccination tested positive with Ct <25, including at least 8 who were asymptomatic at the time of testing.
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 | The Impact of COVID Vaccination on Symptoms of Long COVID. An International Survey of People with Lived Experience of Long COVID | Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern | Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines | Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial | Efficacy of Portable Air Cleaners and Masking for Reducing Indoor Exposure to Simulated Exhaled SARS-CoV-2 Aerosols — United States, 2021